Literature DB >> 28885659

The role of serum neuron-specific enolase in patients with prostate cancer: a systematic review of the recent literature.

Barbara Muoio1, Mariarosa Pascale1, Enrico Roggero1.   

Abstract

In this systematic review, we evaluated the value of serum concentrations of neuron-specific enolase (NSE) in patients with prostate cancer (PCa) in order to clarify the possible role of NSE in the diagnosis, management, treatment and monitoring of PCa. A comprehensive search of the recent literature was conducted to find relevant data on the role of NSE in PCa. Two hundred and eighty-two records were revealed, and 19 articles including 1,772 patients with PCa (either confirmed or suspected) were selected. After reviewing the articles, the major result was that elevated serum NSE appears to correlate with prognosis in advanced PCa, particularly in patients with progressive and metastatic castration-resistant PCa. Based on the existing literature, the role of serum NSE in PCa patients should be further evaluated.

Entities:  

Keywords:  Biomarkers; Neuroendocrine; Neuron-specific enolase; Prognosis; Prostate cancer

Mesh:

Substances:

Year:  2018        PMID: 28885659     DOI: 10.5301/ijbm.5000286

Source DB:  PubMed          Journal:  Int J Biol Markers        ISSN: 0393-6155            Impact factor:   2.659


  9 in total

1.  The VISION Forward: Recognition and Implication of PSMA-/18F-FDG+ mCRPC.

Authors:  Hossein Jadvar
Journal:  J Nucl Med       Date:  2021-12-21       Impact factor: 11.082

2.  A Novel Combination of Serum Markers in a Multivariate Model to Help Triage Patients Into "Low-" and "High-Risk" Categories for Prostate Cancer.

Authors:  Christopher J McNally; Joanne Watt; Mary Jo Kurth; John V Lamont; Tara Moore; Peter Fitzgerald; Hardev Pandha; Declan J McKenna; Mark W Ruddock
Journal:  Front Oncol       Date:  2022-05-19       Impact factor: 5.738

3.  PSMA PET-CT Imaging Predicts Treatment Progression in Men with Biochemically Recurrent Prostate Cancer-A Prospective Study of Men with 3 Year Follow Up.

Authors:  Sean Ong; Claire Pascoe; Brian D Kelly; Zita Ballok; David Webb; Damien Bolton; Declan Murphy; Shomik Sengupta; Patrick Bowden; Nathan Lawrentschuk
Journal:  Cancers (Basel)       Date:  2022-05-31       Impact factor: 6.575

4.  Neuron-specific enolase has potential value as a biomarker for [18F]FDG/[68Ga]Ga-PSMA-11 PET mismatch findings in advanced mCRPC patients.

Authors:  Florian Rosar; Kalle Ribbat; Martin Ries; Johannes Linxweiler; Mark Bartholomä; Stephan Maus; Mathias Schreckenberger; Samer Ezziddin; Fadi Khreish
Journal:  EJNMMI Res       Date:  2020-05-24       Impact factor: 3.138

5.  Expression patterns and clinical significances of ENO2 in lung cancer: an analysis based on Oncomine database.

Authors:  Desen Liu; Yiming Mao; Cheng Chen; Feng Zhu; Wenqiang Lu; Haitao Ma
Journal:  Ann Transl Med       Date:  2020-05

6.  Upregulation of erythropoietin and erythropoietin receptor in castration-resistant progression of prostate cancer.

Authors:  Chen Ye; Guang-Hua Chen; Xin Chen; Sheng-Fei Qin; Min-Feng Shi; Tie Zhou
Journal:  Asian J Androl       Date:  2020 Jul-Aug       Impact factor: 3.285

7.  Serum markers change for intraocular metastasis in renal cell carcinoma.

Authors:  Tie Sun; Jing Tang; Yi-Cong Pan; Chen-Yu Yu; Biao Li; Li-Juan Zhang; Hui-Ye Shu; Qian-Min Ge; Yi Shao
Journal:  Biosci Rep       Date:  2021-09-30       Impact factor: 3.840

8.  Evaluation of Blood-based Biomarkers for Prediction of Response in Carboplatin-treated Metastatic Castration-resistant Prostate Cancer Patients.

Authors:  Jennifer Moritz; Thomas Bauernhofer; Sebastian Mannweiler; Tanja Langsenlehner; Karl Pummer; Nadia Dandachi; Martin Pichler
Journal:  In Vivo       Date:  2020 Nov-Dec       Impact factor: 2.155

Review 9.  Regulation of Neuroendocrine-like Differentiation in Prostate Cancer by Non-Coding RNAs.

Authors:  Eva Slabáková; Zuzana Kahounová; Jiřina Procházková; Karel Souček
Journal:  Noncoding RNA       Date:  2021-12-02
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.